Clinical InvestigationPreliminary Case-control Study to Evaluate Diagnostic Values of C-Reactive Protein and Erythrocyte Sedimentation Rate in Differentiating Active Crohn’s Disease From Intestinal Lymphoma, Intestinal Tuberculosis and Behcet’s Syndrome
Section snippets
Ethical Consideration
This study was approved by the Ethics Committee of Jinling Hospital, Medical School of Nanjing University.
Study Population
This is a hospital-based case-control study. The study population included patients newly diagnosed as active CD and registered in the electronical Jinling Hospital inflammatory bowel disease (IBD) database between January 2008 and December 2011. Controls, including IL, ITB and BD, were individuals newly diagnosed in the same period and age, gender, body mass index and geographically
Demographic Information
Twenty-nine active CD, 25 IL, 30 ITB and 17 BD patients were collected in this study. Age, gender, body mass index (Table 1) and geographic distribution (data not shown) were similar among these groups. All enrolled patients were homogenous Chinese.
According to the Montreal classification of Crohn’s disease,10 L1 (ileal) was the most common disease location (41.4%) and B2 (stricturing) was the most common disease behavior (48.3%) in CD group. The CDAI score was 238.6 = 12.5 with maximum and
DISCUSSION
In clinical care of patients with IBD, biomarkers are currently used in conjunction with invasive testing, such as endoscopy and radiology, to support making diagnosis,11., 12. differentiating between CD and ulcerative colitis (UC),13., 14. monitoring disease activity12., 15. and predicting responses to therapy.16., 17. During the last decade, a series of serological and fecal biomarkers has brought significant concerns in the field of IBD.
For many reasons, blood-based biomarkers seem to be
REFERENCES (30)
- et al.
Inflammatory bowel disease: clinical aspects and established and evolving therapies
Lancet
(2007) - et al.
Long-term clinical outcomes of Crohn’s disease and intestinal Behcet’s disease
Inflamm Bowel Dis
(2013) - et al.
Biomarkers in inflammatory bowel disease: current practices and recent advances
Transl Res
(2012) - et al.
Behcet’s disease—a contemporary review
J Autoimmun
(2009) - et al.
Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease
Clin Gastroenterol Hepatol
(2008) - et al.
Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease
Gastroenterology
(1998) - et al.
Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn’s disease
Am J Gastroenterol
(2002) - et al.
C-reactive protein as an aid in the differentiation of functional and inflammatory bowel disorders
Clin Chim Acta
(1985) - et al.
Long-term complications, extraintestinal manifestations, and mortality in adult Crohn’s disease in population-based cohorts
Inflamm Bowel Dis
(2011) - et al.
Differential diagnosis between Crohn’s disease and intestinal tuberculosis in China
Int J Clin Pract
(2006)
The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease
Gastroenterology
World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010
Inflamm Bowel Dis
Criteria for diagnosis of Behcet’s disease. International Study Group for Behcet’s Disease
Lancet
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications
Gut
Review of fecal biomarkers in inflammatory bowel disease
Dis Colon Rectum
Cited by (39)
Identification of depression in patients with acute coronary syndrome using multiple serum biomarkers
2024, General Hospital PsychiatryHigh sensitive and selective C-reactive protein detection by means of lossy mode resonance based optical fiber devices
2017, Biosensors and BioelectronicsCitation Excerpt :CRP measuring is not specific for any condition but it is a fairly sensitive biomarker of inflammation and has been proven very useful in determining disease progress as well as the effectiveness of treatments in inflammations, infections, tissue necrosis, surgery, burns, cancer, cardiovascular diseases or coronary heart disease risk (Danesh et al., 2004; Lau et al., 2005; Llombart et al., 2013; Pepys and Hirschfield, 2003). Thus, CRP has emerged as an effective disease biomarker in human body with an even more sensitive and accurate reflection of the acute phase response than the ESR (Erythrocyte Sedimentation Rate) in some cases (Liu et al., 2013). The median concentration of CRP is 0.8 mg/L and always less than 12 mg/L in apparently healthy individuals with higher values in elder people.
Predicting bacteria causing acute bacterial rhinosinusitis by clinical features
2020, Brazilian Journal of OtorhinolaryngologyCitation Excerpt :The serum CRP is increased in response to inflammation following interleukin-6 secretion by macrophages and T cells.12,13 Compared to ESR, the CRP is more sensitive in identifying the increased inflammatory responses.14 The ESR may be normal while the CRP is elevated.
Ileocecal involvement in intestinal Behçet's disease and Crohn's disease: comparison of clinicopathological and immunophenotypic features
2023, Journal of Digestive DiseasesErythrocyte Sedimentation Rate: A Physics-Driven Characterization in a Medical Context
2023, Journal of Visualized Experiments
This work was supported by from the National Nature Science Foundation of China Grant 81270478/H0312 and the Climb Program in Natural Science Foundation of Jiangsu Province for Distinguished Scholars Grant BK2010017.
The authors have no financial or other conflicts of interest to disclose.